Vadadustat - Akebia Therapeutics
Alternative Names: AKB-6548; MT 6548; PG 1016548; VAFSEO; VafseoLatest Information Update: 14 Aug 2024
At a glance
- Originator Procter & Gamble
- Developer Akebia Therapeutics; MEDICE; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical
- Class Acetic acids; Amides; Antianaemics; Antivirals; Chlorobenzenes; Chlorophenols; Pyridines; Small molecules; Urologics
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaemia
- Phase II Renal failure; SARS-CoV-2 acute respiratory disease